Protocol Ledger

NCT03433755 · Phase III · TERMINATED

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Interventional Phase III clinical trial protocol NCT03433755 sponsored by Amgen in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-09 Enrollment: 259 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03433755
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)259 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03433755
Protocol FieldVerified Registry Value
NCT IdentifierNCT03433755
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment259 participants (ACTUAL)
Registered Start Date2019-05-09
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI